title: Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
abstract: Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. lmarsh@jhmi.edu
authors.forename: Laura
authors.initials: L
authors.lastname: Marsh
authors.forename: Kevin
authors.initials: K
authors.lastname: Biglan
authors.forename: Melissa
authors.initials: M
authors.lastname: Gerstenhaber
authors.forename: James R
authors.initials: JR
authors.lastname: Williams
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001714:Bipolar Disorder / Q000139:chemically induced; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications* / Q000523:psychology; D010865:Pilot Projects; D017397:Prefrontal Cortex / Q000187:drug effects / Q000503:physiopathology; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011581:Psychological Tests; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000978:Antiparkinson Agents; D018697:Nootropic Agents; D011437:Propylamines; D011619:Psychotropic Drugs; D000069445:Atomoxetine Hydrochloride